# Tazemetostat Expanded Access Program for Adults With Epithelioid Sarcoma

> **NCT04225429** · — · NO_LONGER_AVAILABLE · sponsor: **Epizyme, Inc.**

## Conditions studied

- Epithelioid Sarcoma

## Interventions

- **DRUG:** Tazemetostat

## Key facts

- **NCT ID:** NCT04225429
- **Lead sponsor:** Epizyme, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2024-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04225429

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04225429, "Tazemetostat Expanded Access Program for Adults With Epithelioid Sarcoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04225429. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*